{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:07:01Z","timestamp":1785517621434,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40266-026-01310-z","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:30:20Z","timestamp":1782131420000},"page":"661-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gabapentinoid Use and Risk of Alzheimer\u2019s Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4789-6019","authenticated-orcid":false,"given":"Anderson Matheus Pereira","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana","family":"Menegucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda Liphaus Almeida","family":"Negreli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda Scheffer","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Rodrigues","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ocilio Ribeiro","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Dornellys","family":"da Silva Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Noleto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Haddad","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipe Silveira","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryvelton","family":"de Souza Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bernadete","family":"de Sousa Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1310_CR1","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325."},{"issue":"10452","key":"1310_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet. 2024;404(10452):572\u2013628.","journal-title":"Lancet"},{"issue":"5","key":"1310_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMp1704633","volume":"377","author":"CW Goodman","year":"2017","unstructured":"Goodman CW, Brett AS. Gabapentin and pregabalin for pain: is increased prescribing a cause for concern? N Engl J Med. 2017;377(5):411\u20134.","journal-title":"N Engl J Med"},{"issue":"5","key":"1310_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","volume":"179","author":"CW Goodman","year":"2019","unstructured":"Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med. 2019;179(5):695\u2013701.","journal-title":"JAMA Intern Med"},{"key":"1310_CR5","first-page":"117822181880131","volume":"12","author":"AM Peckham","year":"2018","unstructured":"Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for off-label use: evidence-based or cause for concern? Subst Abuse. 2018;12:1178221818801311.","journal-title":"Subst Abuse"},{"issue":"3","key":"1310_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013433","volume":"7","author":"KT Houghton","year":"2017","unstructured":"Houghton KT, Forrest A, Awad A, Atkinson LZ, Stockton S, Harrison PJ, et al. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open. 2017;7(3):e013433.","journal-title":"BMJ Open"},{"issue":"1","key":"1310_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2024.105363","volume":"26","author":"JD Winter","year":"2025","unstructured":"Winter JD, Kerns JW, Qato DM, Winter KM, Brandt N, Wastila L, et al. A nursing home clinician survey to explain gabapentinoid increases. J Am Med Dir Assoc. 2025;26(1):105363.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"1310_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bcp.15532","volume":"89","author":"GY Oh","year":"2023","unstructured":"Oh GY, Moga DC, Abner EL. Gabapentin utilization among older adults with different cognitive statuses enrolled in the National Alzheimer\u2019s Coordinating Center (2006\u20132019). Br J Clin Pharmacol. 2023;89(1):410\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1310_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neuropharm.2003.11.010","volume":"46","author":"K Bayer","year":"2004","unstructured":"Bayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P\/Q-type Ca2+ channels. Neuropharmacology. 2004;46(5):743\u20139.","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"1310_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pain.2008.11.019","volume":"142","author":"CP Taylor","year":"2009","unstructured":"Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin: calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain. 2009;142(1\u20132):13\u20136.","journal-title":"Pain"},{"issue":"2","key":"1310_CR11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.cell.2009.09.025","volume":"139","author":"C Eroglu","year":"2009","unstructured":"Eroglu C, Allen NJ, Susman MW, O\u2019Rourke NA, Park CY, Ozkan E, et al. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell. 2009;139(2):380\u201392.","journal-title":"Cell"},{"issue":"2","key":"1310_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/syn.10247","volume":"50","author":"S Bertrand","year":"2003","unstructured":"Bertrand S, Nouel D, Morin F, Nagy F, Lacaille JC. Gabapentin actions on Kir3 currents and N-type Ca2+ channels via GABAB receptors in hippocampal pyramidal cells. Synapse. 2003;50(2):95\u2013109.","journal-title":"Synapse"},{"issue":"1","key":"1310_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2005.12.084","volume":"1075","author":"F Bian","year":"2006","unstructured":"Bian F, Li Z, Offord J, Davis MD, McCormick J, Taylor CP, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006;1075(1):68\u201380.","journal-title":"Brain Res"},{"issue":"7","key":"1310_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40266-024-01130-z","volume":"41","author":"G Oh","year":"2024","unstructured":"Oh G, Moga DC, Fardo DW, Harp JP, Abner EL. The association of gabapentin initiation with cognitive and behavioral changes in older adults with cognitive impairment: a retrospective cohort study. Drugs Aging. 2024;41(7):623\u201332.","journal-title":"Drugs Aging"},{"key":"1310_CR15","doi-asserted-by":"publisher","first-page":"1193108","DOI":"10.3389\/fnagi.2023.1193108","volume":"15","author":"N Bornier","year":"2023","unstructured":"Bornier N, Mulliez A, Chenaf C, Elyn A, Teixeira S, Authier N, et al. Chronic pain is a risk factor for incident Alzheimer\u2019s disease: a nationwide propensity-matched cohort using administrative data. Front Aging Neurosci. 2023;15:1193108.","journal-title":"Front Aging Neurosci."},{"key":"1310_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jad.2024.05.031","volume":"358","author":"SE Tsai","year":"2024","unstructured":"Tsai SE, Yang SF, Wang YH, Yeh CB. Association between gabapentin use and risk of dementia in adults with chronic pain: a nested case\u2013control study. J Affect Disord. 2024;358:205\u201310.","journal-title":"J Affect Disord"},{"key":"1310_CR17","doi-asserted-by":"publisher","first-page":"1128601","DOI":"10.3389\/fphar.2023.1128601","volume":"14","author":"YH Huang","year":"2023","unstructured":"Huang YH, Pan MH, Yang HI. The association between gabapentin or pregabalin use and the risk of dementia: an analysis of the National Health Insurance Research Database in Taiwan. Front Pharmacol. 2023;14:1128601.","journal-title":"Front Pharmacol"},{"key":"1310_CR18","doi-asserted-by":"publisher","unstructured":"Eghrari NB, Yazji IH, Yavari B, Van Acker GM, Kim CH. Risk of dementia following gabapentin prescription in chronic low back pain patients, Regional Anesthesia & Pain Medicine, 2025. https:\/\/doi.org\/10.1136\/rapm-2025-106577.","DOI":"10.1136\/rapm-2025-106577"},{"issue":"1","key":"1310_CR19","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","volume":"14","author":"AYL Chan","year":"2023","unstructured":"Chan AYL, Yuen ASC, Tsai DHT, Lau WCY, Jani YH, Hsia Y, et al. Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study. Nat Commun. 2023;14(1):5005.","journal-title":"Nat Commun"},{"key":"1310_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.","journal-title":"BMJ"},{"issue":"10","key":"1310_CR21","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10(10):ED000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"1310_CR22","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"issue":"7","key":"1310_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"key":"1310_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2024.108602","volume":"186","author":"JPT Higgins","year":"2024","unstructured":"Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024;186:108602.","journal-title":"Environ Int"},{"issue":"11","key":"1310_CR25","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med. 2002;21(11):1559\u201373.","journal-title":"Stat Med"},{"issue":"1","key":"1310_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jrsm.5","volume":"1","author":"LV Hedges","year":"2010","unstructured":"Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. Res Synth Methods. 2010;1(1):39\u201365.","journal-title":"Res Synth Methods."},{"issue":"7414","key":"1310_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"4","key":"1310_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Mental Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Mental Health."},{"issue":"7650","key":"1310_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"1310_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.910719","volume":"13","author":"G Oh","year":"2022","unstructured":"Oh G, Moga DC, Fardo DW, Abner EL. The association of gabapentin initiation and neurocognitive changes in older adults with normal cognition. Front Pharmacol. 2022;13:910719.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1310_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13195-025-01825-4","volume":"17","author":"D Qureshi","year":"2025","unstructured":"Qureshi D, Allen NE, Kuzma E, Littlejohns TJ. Metabolic syndrome and risk of incident all-cause dementia, Alzheimer\u2019s disease and vascular dementia: a systematic review and meta-analysis of longitudinal studies. Alzheimers Res Ther. 2025;17(1):198.","journal-title":"Alzheimers Res Ther."},{"issue":"11","key":"1310_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1177\/0269881113503509","volume":"27","author":"DS Baldwin","year":"2013","unstructured":"Baldwin DS, Aitchison K, Bateson A, Curran HV, Davies S, Leonard B, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967\u201371.","journal-title":"J Psychopharmacol"},{"key":"1310_CR33","doi-asserted-by":"crossref","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des troubles a. McGill U, Antony MM, Bouchard S, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl. 1):S1.","DOI":"10.1186\/1471-244X-14-S1-S1"},{"key":"1310_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jad.2024.01.029","volume":"349","author":"LY Ma","year":"2024","unstructured":"Ma LY, Ou YN, Gao PY, Fu Y, Zhang DD, Yang L, et al. Associations between antipsychotics exposure and dementia risk: a prospective cohort study of 415,100 participants. J Affect Disord. 2024;349:201\u20139.","journal-title":"J Affect Disord"},{"key":"1310_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fnagi.2019.00344","volume":"11","author":"M Ettcheto","year":"2019","unstructured":"Ettcheto M, Olloquequi J, Sanchez-Lopez E, Busquets O, Cano A, Manzine PR, et al. Benzodiazepines and related drugs as a risk factor in Alzheimer\u2019s disease dementia. Front Aging Neurosci. 2019;11:344.","journal-title":"Front Aging Neurosci."},{"issue":"4","key":"1310_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bcp.13844","volume":"85","author":"T Supasitthumrong","year":"2019","unstructured":"Supasitthumrong T, Bolea-Alamanac BM, Asmer S, Woo VL, Abdool PS, Davies SJC. Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report. Br J Clin Pharmacol. 2019;85(4):690\u2013703.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1310_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0269881117744996","volume":"32","author":"SJ Davies","year":"2018","unstructured":"Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer\u2019s and mixed dementia. J Psychopharmacol. 2018;32(5):509\u201323.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"1310_CR38","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.celrep.2018.02.021","volume":"22","author":"J Chen","year":"2018","unstructured":"Chen J, Li L, Chen SR, Chen H, Xie JD, Sirrieh RE, et al. The alpha2delta-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell Rep. 2018;22(9):2307\u201321.","journal-title":"Cell Rep"},{"issue":"10","key":"1310_CR39","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jagp.2016.05.015","volume":"24","author":"B Gulpers","year":"2016","unstructured":"Gulpers B, Ramakers I, Hamel R, Kohler S, Oude Voshaar R, Verhey F. Anxiety as a predictor for cognitive decline and dementia: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2016;24(10):823\u201342.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"1310_CR40","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41380-021-01386-6","volume":"27","author":"JSW Hong","year":"2022","unstructured":"Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale. Mol Psychiatry. 2022;27(3):1339\u201349.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1310_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1747-4949.2011.00731.x","volume":"7","author":"R Sahathevan","year":"2012","unstructured":"Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012;7(1):61\u201373.","journal-title":"Int J Stroke"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-026-01310-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-026-01310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:26:43Z","timestamp":1785515203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-026-01310-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s40266-026-01310-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AMPS, ESF, MBSM, AMPS, ML, GM, MFLAN, MESV, IRM, ORG, JDSL, GN, DHS, and FSD have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AMPS, ESF, and MBSM conceived and designed the study. AMPS, ML, GM, MFLAN, MESV, IRM, and ORG performed data curation and conducted the statistical analyses. ML, GM, and MFLAN performed the risk-of-bias assessments. JDSL, GN, DHS, and FSD provided methodological supervision and critically revised the manuscript. GP, FSD, and MBSM contributed to interpretation of findings and substantive revisions. All authors contributed to data interpretation and reviewed and approved the final manuscript, and all authors have read and approved the final version.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}